Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis

Hui Li; Dongwen Wu; Shupeng Shi; Yadong Xu; Ling Wei; Jing Liu; Yanting Liu

doi:10.18632/oncotarget.17376

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis

Hui Li _, Dongwen Wu, Shupeng Shi, Yadong Xu, Ling Wei, Jing Liu and Yanting Liu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:51331-51344. https://doi.org/10.18632/oncotarget.17376

Metrics: PDF 1144 views | HTML 2206 views | ?

Abstract

Hui Li1,*, Dongwen Wu2,*, Shupeng Shi2, Yadong Xu2, Ling Wei2, Jing Liu2 and Yanting Liu2

1Reproductive Department, Xiangya Hospital, Central South University, Changsha, China

2Xiangya School of Medicine, Central South University, Changsha, China

*These authors have contributed equally to this work

Correspondence to:

Hui Li, email: [email protected]

Keywords: renal cell carcinoma, CD147, case control study, meta-analysis

Received: September 26, 2016 Accepted: February 21, 2017 Published: April 10, 2017

ABSTRACT

Objective: To assess clinical significance of CD147 in renal cell carcinoma.

Methods: Collect case-control studies which focus on CD147’s expression in renal cell carcinoma. Trails were retrieved from CBM, CNKI, Wan-fang database, PubMed, Cochrane Library and Embase. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently, and outcomes were pooled with Revman5.3 and STATA14.0.

Results: A total of 11 studies were confirmed, among which renal cell carcinoma 887 cases, non-cancer 505cases. As for the positive rate of CD147, there are statistical differences among survival, renal cell carcinoma tissue vs. non-cancer tissues [OR= 8.19, P= 0.0002], with vs. without lymph node metastases [OR= 6.52, P= 0.001], clinical stage III~IV vs. II~I [OR= 4.07, P< 0.00001], histopathological stage III~IV vs. II [OR= 3.01, P= 0.002], histopathological stage III~IV vs. I [OR= 7.50, P< 0.00001], tumor size [OR= 5.01, P= 0.0007]. No significant difference was tested among different age, gender, histological types and Position of cancer.

Conclusion: As shown in our results, CD 147 may participate the whole course of carcinogenesis of renal cell carcinoma, which might be valuable for the diagnosis, treatment and prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17376

Publication Alerts

Research Papers:

Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis

Abstract